Prime Editing stands out as a more advanced technology in gene editing than CRISPR and base editing. Its difference lies in its ability to work without breaking the DNA double helix, employing a "find and replace" logic similar to a word processor. This means much more precise editing, a much lower risk of targeting the wrong end, and the potential to treat a much wider range of diseases.
Many investors are currently focused on the company's short-term goals: Will the initial clinical data be sustainable? Will the new clinical trial applications planned for 2026 be approved? Will the Cystic Fibrosis program progress? However, the crucial point is this: Current CRISPR methods break DNA, carrying risks. There are currently no treatments for hundreds of genetic diseases. Prime Editing's precise approach offers a real hope for a cure in complex genetic diseases that are currently untreatable.
They achieve this promise with a technology that works with a guide called pegRNA and a special enzyme; it can perform deletions, insertions, and all genetic letter changes. This offers a flexibility that surpasses the limitations of classic CRISPR. In the first human trial for Chronic Granulomatous Disease (CGD), two patients showed signs of rapid improvement and a remission rate of over 69%. The safety profile was excellent, with no serious side effects. These results provided the first evidence that Prime Editing works in humans and were published in a prestigious medical journal. Those interested can read it.
They may be modern-day adversaries, but they share a common past. $PRME's roots lie in the same lab as Beam Therapeutics, and they were working under an agreement made in 2019. However, conflicting claims continue, particularly in areas like AATD. The case is expected to be resolved in the first quarter of 2026, and I believe Prime will win, but this is, of course, just a guess. Prime's ability to target a wider range of mutations is a critical advantage here. A general LNP carrier system developed for liver diseases (Wilson's and AATD) could provide rapid progress. For cystic fibrosis, specialized strategies supported by the Cystic Fibrosis Foundation are being used.
Management recently announced a decision to focus its projects on three main diseases (Wilson's disease, AATD, and cystic fibrosis). This is partly due to layoffs and poor financial performance. Instead of trying to keep up with everything, it means concentrating on areas that create value. The collaboration with BMS also preserves the potential in immune cell (T-cell) therapies. Management emphasizes that 2027 will be the year of significant clinical data, keeping expectations realistic.
I love using this phrase. It's typical for a clinical-stage biotechnology company: the better the technology and vision, the worse the finances are – revenue is negligible, and they burn about $50 million in cash each quarter. However, in the third quarter of 2025, they had approximately $227 million in cash assets, which is considered sufficient to keep operations going until 2027. The company's market capitalization is currently low. However, it would be a mistake to evaluate the company solely on these numbers; the potential of its platform to become the standard for "precision regulation" across a wide range of disease areas is far more significant. Of course, this is conditional on winning the lawsuit against Beam.
Regulations in the US are always a concern, but if successful, this can turn into an advantage. Positive initial human data could accelerate subsequent processes. Collaboration with BMS and support from the Cystic Fibrosis Foundation provide additional confidence. Compared to competitors' technologies (Beam's scope is narrower, while other CRISPR companies risk DNA manipulation), Prime Editing's advantages become apparent.
To summarize, the story of $PRME currently has two sides: on one hand, there are short-term risks such as the rate at which cash is being burned, dilution risk, delays, and the ongoing dispute with Beam. On the other hand, there is a grand success scenario that is not yet fully realized. If clinical trial applications in 2026 and initial data in 2027 are positive, the company could go from being just a gene editing company to becoming a fundamental treatment platform for many genetic diseases. This could mean a very different share price than it is today. Or, the company could go bankrupt, it's that simple.
Therefore, if you are going to invest, you need to look at $PRME not in terms of short-term data and financial noise, but in terms of the transformative potential it will bring in 2027 and beyond. This is a long-term technology platform investment with high risk but high return potential. Personally, I don't include it in my portfolio because the valuation is high and volatile compared to clinical risks. However, if the positive scenario occurs, the returns could be very high. That's why it's on my watchlist, and I find it logical to take a small position. I also don't plan to do this with 3-5 options dated 2028.
The information, comments and recommendations contained herein are not within the scope of investment consultancy. Investment consultancy services are provided within the framework of the investment consultancy agreement to be signed between brokerage firms, portfolio management companies, banks that do not accept deposits and customers. The comments in this article are only my personal comments and these comments may not be appropriate for your financial situation and risk return. For this reason, investments should not be made based on the information and comments in my articles.
